NCT05236868

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-42847922 (Seltorexant) Administered as Oral Tablet and an Intravenous Microdose of 14C-seltorexant in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the absolute bioavailability of seltorexant in healthy participants following a single oral dose of seltorexant and an intravenous (IV) infusion dose of 14C-seltorexant.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Seltorexant	Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.

Timeline

• Start date: 2022-02-03
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2022-02-11
• Last updated: 2025-04-27

Locations

1 site across 1 country: Netherlands

Regulatory

• FDA-regulated drug study